Lea Duvnjak

Lea Duvnjak

Auto-generated profile, based on publicly available information

Lea Duvnjak

University of Zagreb

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SSSanja Stojsavljević
Sanja Stojsavljević
MPMarija Gomerčić Palčić
Marija Gomerčić Palčić
LJLucija Virović Jukić
Lucija Virović Jukić
LDLea Smirčić Duvnjak
Lea Smirčić Duvnjak
MDMarko Duvnjak
Marko Duvnjak
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of a patient with no history of alcohol abuse or other causes for secondary hepatic steatosis. The pathogenesis of NAFLD and nonalcoholic steatohepatitis (NASH) has not been fully elucidated. The “two-hit“ hypothesis is probably a too simplified model to elaborate complex pathogenetic events occurring in patients with NASH. It should be better regarded as a multiple step process, with accumulation of liver fat being the first step, followed by the development of necroinflammation and fibrosis. Adipose tissue, which has emerged as an endocrine organ with a key role in energy homeostasis, is responsive to both central and peripheral metabolic signals and is itself capable of secreting a number of proteins. These adipocyte-specific or enriched proteins, termed adipokines, have been shown to have a variety of local, peripheral, and central effects. In the current review, we explore the role of adipocytokines and proinflammatory cytokines in the pathogenesis of NAFLD. We particularly focus on adiponectin, leptin and ghrelin, with a brief mention of resistin, visfatin and retinol-binding protein 4 among adipokines, and tumor necrosis factor-α, interleukin (IL)-6, IL-1, and briefly IL-18 among proinflammatory cytokines. We update their role in NAFLD, as elucidated in experimental models and clinical practice.

1 February 2017 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
Vladimir VuksanVladimir Vuksan
Vladimir Vuksan
AJA.L. Jenkins
A.L. Jenkins
CBC. Brissette
C. Brissette
LCL. Choleva
L. Choleva
EJE. Jovanovski
E. Jovanovski
AHA. Hanna
A. Hanna

1 May 2017 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
HHHoang Vi Thanh Ho
Hoang Vi Thanh Ho
EJElena Jovanovski
Elena Jovanovski
AZAndreea Zurbau
Andreea Zurbau
SMSonia Blanco Mejia
Sonia Blanco Mejia
JSJohn L Sievenpiper
John L Sievenpiper
Vladimir VuksanVladimir Vuksan
Vladimir Vuksan
Background: Evidence from randomized controlled trials (RCTs) suggests the consumption of konjac glucomannan (KJM), a viscous soluble fiber, for improving LDL-cholesterol concentrations. It has also been suggested that the cholesterol-lowering potential of KJM may be greater than that of other fibers. However, trials have been relatively scarce and limited in sample size and duration, and the effect estimates have been inconsistent. The effect of KJM on new lipid targets of cardiovascular disease (CVD) risk is also unknown.

21 December 2016 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
VVV Vuksan
V Vuksan
LCL Choleva
L Choleva
EJE Jovanovski
E Jovanovski
AJA L Jenkins
A L Jenkins
FAF Au-Yeung
F Au-Yeung
LDL Duvnjak
L Duvnjak

24 February 2018 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
Vladimir VuksanVladimir Vuksan
Vladimir Vuksan
ZXZenith Zheng Xu
Zenith Zheng Xu
EJElena Jovanovski
Elena Jovanovski
AJAlexandra L. Jenkins
Alexandra L. Jenkins
UBUljana Beljan-Zdravkovic
Uljana Beljan-Zdravkovic
MLMichael Z. C. Li
Michael Z. C. Li

1 May 2017 in Medicine
Verified
Journal Article
Open access
PDF file
EJElena Jovanovski
Elena Jovanovski
DLDandan Li
Dandan Li
HHHoang Vi Thanh Ho
Hoang Vi Thanh Ho
VDVladimir Djedovic
Vladimir Djedovic
AMAny de Castro Ruiz Marques
Any de Castro Ruiz Marques
Vladimir VuksanVladimir Vuksan
Vladimir Vuksan
Polyunsaturated fats (PUFAs) have been shown to reduce type 2 diabetes (T2DM) risk and improve insulin responsiveness in T2DM subjects, but whether the plant sources of omega-3 PUFA (alpha-linolenic acid [ALA]) have an effect on glycemic control requires further investigation. The parameters of interest were glycated hemoglobin (HbA1c), fasting blood glucose (FBG), fasting blood insulin (FBI), homeostatic model assessment for insulin resistance (HOMA-IR), fructosamine, and glycated albumin. A comprehensive search was conducted with MEDLINE, Embase, CINAHL, and Cochrane. Eligible studies included randomized controlled trials (RCTs) ≥1 month in duration that compared diets enriched in ALA with usual diets on glycemic parameters. For each study, the risk of bias as well as the study quality was assessed. Using the statistical software RevMan (v5.3), data were pooled using the generic inverse method with random effects model, and final results were expressed as mean differences (MD) with 95% confidence intervals (CI). Heterogeneity was assessed by the Cochran Q statistic and quantified by the I2 statistic. A total of 8 trials (N = 212) were included in the meta-analysis. Compared to a control diet, a median dose of 4.4 g/day of ALA intake for a median duration of 3 months did not affect HbA1c (%) (MD = –.01; [95%: –.32, .31], P = .96). A median ALA dose of 5.4 g/day did not lower FBG (MD = .07; [95% CI: –.61, .76], P = .84) or FBI (MD = 7.03, [95% CI: –5.84, 19.89], P = .28). Summary effect estimates were generally compromised by considerable and unexplained heterogeneity (I2 ≥75%). In the subgroup analysis of continuous predictors, a reduction in HbA1c (%) and FBG (mmol/L) was significantly associated with an increased intake of ALA. Further adjustment for Publication Bias using Duval and Tweedie's trim-and-fill analysis provided an adjusted, significant MD of –.25 (95% CI: –.38, –.12; P <.001) for HbA1c (%). ALA-enriched diets did not affect HbA1c, FBG, or FBI. The scarce number of existing RCTs and the presence of heterogeneity in our meta-analysis limit the ability to make firm conclusions about ALA in T2DM management. The potential for ALA to have dose-dependent effects warrants further research in this area.